Symbols / COGT
COGT Chart
About
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.36B |
| Enterprise Value | 5.74B | Income | -328.94M | Sales | — |
| Book/sh | 3.40 | Cash/sh | 5.59 | Dividend Yield | — |
| Payout | 0.00% | Employees | 258 | IPO | — |
| P/E | — | Forward P/E | -63.76 | PEG | — |
| P/S | — | P/B | 11.54 | P/C | — |
| EV/EBITDA | -17.34 | EV/Sales | — | Quick Ratio | 14.09 |
| Current Ratio | 14.23 | Debt/Eq | 37.52 | LT Debt/Eq | — |
| EPS (ttm) | -2.16 | EPS next Y | -0.61 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-05 | ROA | -32.93% |
| ROE | -73.70% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 162.31M |
| Shs Float | 150.88M | Short Float | 12.36% | Short Ratio | 6.84 |
| Short Interest | — | 52W High | 43.73 | 52W Low | 3.72 |
| Beta | 0.47 | Avg Volume | 2.29M | Volume | 1.52M |
| Target Price | $53.83 | Recom | Strong_buy | Prev Close | $37.06 |
| Price | $39.18 | Change | 5.72% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$53.83
Mean price target
2. Current target
$39.18
Latest analyst target
3. DCF / Fair value
$-16.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$39.18
Low
$35.00
High
$72.00
Mean
$53.83
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-18 | main | Piper Sandler | Overweight → Overweight | $52 |
| 2026-01-21 | reit | Wedbush | Outperform → Outperform | $55 |
| 2026-01-06 | main | HC Wainwright & Co. | Buy → Buy | $52 |
| 2025-12-19 | main | JP Morgan | Overweight → Overweight | $67 |
| 2025-12-08 | reit | Needham | Hold → Hold | — |
| 2025-11-13 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-11-11 | main | Baird | Neutral → Neutral | $34 |
| 2025-11-10 | main | Leerink Partners | Outperform → Outperform | $50 |
| 2025-11-04 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2025-10-21 | main | JP Morgan | Overweight → Overweight | $44 |
| 2025-10-16 | init | Stifel | — → Hold | $16 |
| 2025-09-03 | init | Raymond James | — → Strong Buy | $30 |
| 2025-08-25 | main | Guggenheim | Buy → Buy | $20 |
| 2025-08-07 | main | JP Morgan | Overweight → Overweight | $30 |
| 2025-08-06 | main | HC Wainwright & Co. | Buy → Buy | $21 |
| 2025-07-18 | main | Citigroup | Buy → Buy | $22 |
| 2025-07-10 | main | JP Morgan | Overweight → Overweight | $29 |
| 2025-07-08 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2025-07-08 | reit | Guggenheim | Buy → Buy | $17 |
| 2025-07-08 | main | Baird | Neutral → Neutral | $9 |
- Cogent Biosciences, Inc. $COGT Stock Position Cut by NEOS Investment Management LLC - MarketBeat Sat, 21 Feb 2026 11
- Cogent Biosciences Balances Bezuclastinib Phase 3 Progress With Dilution Risk - simplywall.st ue, 24 Feb 2026 23
- Cogent Biosciences, Inc. (COGT) Stock Analysis: Biotechnology Innovator With 40% Upside Potential - DirectorsTalk Interviews Sat, 21 Feb 2026 06
- COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know - Yahoo Finance hu, 20 Nov 2025 08
- COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know - Zacks Investment Research hu, 20 Nov 2025 08
- Insider Sale: Director at $COGT Sells 3,500,000 Shares - Quiver Quantitative Fri, 23 Jan 2026 08
- Cogent (Nasdaq: COGT) commences $200M convertible notes due 2031 and stock offering - Stock Titan Mon, 10 Nov 2025 08
- Cogent Biosciences: Time For A Pause (NASDAQ:COGT) - Seeking Alpha Mon, 15 Dec 2025 08
- Commit To Buy Cogent Biosciences At $25, Earn 17.2% Using Options - Nasdaq hu, 05 Feb 2026 08
- Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough - The Motley Fool ue, 17 Feb 2026 17
- Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Cogent Biosciences (COGT) - The Globe and Mail hu, 19 Feb 2026 00
- Readystate Asset Management LP Takes $714,000 Position in Cogent Biosciences, Inc. $COGT - MarketBeat hu, 19 Feb 2026 11
- Cogent Biosciences (NASDAQ: COGT) reports 46% ORR vs 26% in PEAK trial in second-line GIST - Stock Titan Mon, 10 Nov 2025 08
- Cogent Biosciences, Inc. (COGT) Stock Analysis: Exploring a Promising 36% Upside Potential - DirectorsTalk Interviews Fri, 21 Nov 2025 08
- COGENT BIOSCIENCES Earnings Preview: Recent $COGT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Fri, 14 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3500000 | 127400000.0 | — | Sale at price 36.40 per share. | FAIRMOUNT FUNDS MANAGEMENT LLC | Director | — | 2026-01-22 00:00:00 | I |
| 1 | 65000 | 2515500.0 | — | Sale at price 38.70 per share. | KEARNS EVAN D J.D. | Officer | — | 2025-12-26 00:00:00 | D |
| 2 | 77000 | 2978360.0 | — | Sale at price 38.68 per share. | GREEN JOHN L | Chief Financial Officer | — | 2025-12-26 00:00:00 | D |
| 3 | 82642 | 3198245.0 | — | Sale at price 38.70 per share. | SACHS JESSICA M.D. | Officer | — | 2025-12-26 00:00:00 | D |
| 4 | 90000 | 3486600.0 | — | Sale at price 38.74 per share. | ROBINSON JOHN EDWARD | Officer | — | 2025-12-26 00:00:00 | D |
| 5 | 1025000 | — | — | Stock Award(Grant) at price 0.00 per share. | ROBBINS ANDREW R. | Chief Executive Officer | — | 2025-12-17 00:00:00 | D |
| 6 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | KEARNS EVAN D J.D. | Officer | — | 2025-12-17 00:00:00 | D |
| 7 | 350000 | — | — | Stock Award(Grant) at price 0.00 per share. | GREEN JOHN L | Chief Financial Officer | — | 2025-12-17 00:00:00 | D |
| 8 | 370000 | — | — | Stock Award(Grant) at price 0.00 per share. | SACHS JESSICA M.D. | Officer | — | 2025-12-17 00:00:00 | D |
| 9 | 370000 | — | — | Stock Award(Grant) at price 0.00 per share. | ROBINSON JOHN EDWARD | Officer | — | 2025-12-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -271.59M | -204.54M | -141.96M | -73.56M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -255.86M | -192.41M | -140.24M | -72.27M |
| ReconciledDepreciation | 4.35M | 3.59M | 5.88M | 1.99M |
| EBITDA | -271.59M | -204.54M | -141.96M | -73.56M |
| EBIT | -275.94M | -208.13M | -147.84M | -75.55M |
| NetInterestIncome | 18.09M | 13.08M | 3.99M | 467.00K |
| InterestIncome | 18.09M | 13.08M | 3.99M | 467.00K |
| NormalizedIncome | -255.86M | -192.41M | -140.24M | -72.27M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -255.86M | -192.41M | -140.24M | -72.27M |
| TotalExpenses | 275.94M | 208.13M | 147.84M | 75.55M |
| TotalOperatingIncomeAsReported | -275.94M | -208.13M | -147.84M | -75.55M |
| DilutedAverageShares | 110.46M | 79.66M | 58.74M | 43.81M |
| BasicAverageShares | 110.46M | 79.66M | 58.74M | 43.81M |
| DilutedEPS | -2.32 | -2.42 | -2.39 | -1.65 |
| BasicEPS | -2.32 | -2.42 | -2.39 | -1.65 |
| DilutedNIAvailtoComStockholders | -255.86M | -192.41M | -140.24M | -72.27M |
| NetIncomeCommonStockholders | -255.86M | -192.41M | -140.24M | -72.27M |
| NetIncome | -255.86M | -192.41M | -140.24M | -72.27M |
| NetIncomeIncludingNoncontrollingInterests | -255.86M | -192.41M | -140.24M | -72.27M |
| NetIncomeContinuousOperations | -255.86M | -192.41M | -140.24M | -72.27M |
| PretaxIncome | -255.86M | -192.41M | -140.24M | -72.27M |
| OtherIncomeExpense | 1.99M | 2.64M | 3.61M | 2.81M |
| OtherNonOperatingIncomeExpenses | 1.99M | 2.64M | 3.61M | 2.81M |
| SpecialIncomeCharges | 0.00 | |||
| GainOnSaleOfPPE | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 18.09M | 13.08M | 3.99M | 467.00K |
| InterestIncomeNonOperating | 18.09M | 13.08M | 3.99M | 467.00K |
| OperatingIncome | -275.94M | -208.13M | -147.84M | -75.55M |
| OperatingExpense | 275.94M | 208.13M | 147.84M | 75.55M |
| ResearchAndDevelopment | 232.66M | 173.75M | 121.63M | 55.91M |
| SellingGeneralAndAdministration | 43.28M | 34.38M | 26.21M | 19.64M |
| GeneralAndAdministrativeExpense | 43.28M | 34.38M | 26.21M | 19.64M |
| OtherGandA | 43.28M | 34.38M | 26.21M | 19.64M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 110.46M | 86.12M | 69.89M | 43.81M |
| ShareIssued | 110.46M | 86.12M | 69.89M | 43.81M |
| TotalDebt | 17.47M | 18.85M | 19.65M | 3.15M |
| TangibleBookValue | 145.69M | 197.77M | 189.91M | 128.78M |
| InvestedCapital | 145.69M | 197.77M | 189.91M | 128.78M |
| WorkingCapital | 240.76M | 232.60M | 238.12M | 205.56M |
| NetTangibleAssets | 256.29M | 257.80M | 255.74M | 214.18M |
| CapitalLeaseObligations | 17.47M | 18.85M | 19.65M | 3.15M |
| CommonStockEquity | 145.69M | 197.77M | 189.91M | 128.78M |
| PreferredStockEquity | 110.60M | 60.03M | 65.83M | 85.40M |
| TotalCapitalization | 256.29M | 257.80M | 255.74M | 214.18M |
| TotalEquityGrossMinorityInterest | 256.29M | 257.80M | 255.74M | 214.18M |
| StockholdersEquity | 256.29M | 257.80M | 255.74M | 214.18M |
| GainsLossesNotAffectingRetainedEarnings | 447.00K | 246.00K | -104.00K | 0.00 |
| OtherEquityAdjustments | 447.00K | 246.00K | -104.00K | |
| RetainedEarnings | -859.48M | -603.62M | -411.21M | -270.97M |
| AdditionalPaidInCapital | 1.00B | 801.06M | 601.15M | 399.71M |
| CapitalStock | 110.71M | 60.12M | 65.90M | 85.44M |
| CommonStock | 110.00K | 86.00K | 70.00K | 44.00K |
| PreferredStock | 110.60M | 60.03M | 65.83M | 85.40M |
| TotalLiabilitiesNetMinorityInterest | 71.61M | 55.63M | 45.08M | 17.91M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 15.90M | 17.47M | 18.23M | 831.00K |
| LongTermDebtAndCapitalLeaseObligation | 15.90M | 17.47M | 18.23M | 831.00K |
| LongTermCapitalLeaseObligation | 15.90M | 17.47M | 18.23M | 831.00K |
| CurrentLiabilities | 55.71M | 38.17M | 26.85M | 17.08M |
| OtherCurrentLiabilities | 373.00K | 441.00K | 2.10M | 235.00K |
| CurrentDeferredLiabilities | 1.70M | 3.06M | ||
| CurrentDeferredRevenue | 1.70M | 3.06M | ||
| CurrentDebtAndCapitalLeaseObligation | 1.56M | 1.39M | 1.42M | 2.32M |
| CurrentCapitalLeaseObligation | 1.56M | 1.39M | 1.42M | 2.32M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 12.26M | 9.87M | 6.06M | 3.39M |
| PayablesAndAccruedExpenses | 41.51M | 26.47M | 17.26M | 8.07M |
| CurrentAccruedExpenses | 29.50M | 15.81M | 11.42M | 4.59M |
| Payables | 12.01M | 10.65M | 5.84M | 3.48M |
| AccountsPayable | 12.01M | 10.65M | 5.84M | 3.48M |
| TotalAssets | 327.90M | 313.44M | 300.81M | 232.09M |
| TotalNonCurrentAssets | 31.43M | 42.67M | 35.84M | 9.46M |
| OtherNonCurrentAssets | 4.86M | 4.86M | 4.75M | 4.98M |
| InvestmentsAndAdvances | 0.00 | 7.46M | 0.00 | |
| InvestmentinFinancialAssets | 0.00 | 7.46M | 0.00 | |
| AvailableForSaleSecurities | 7.46M | |||
| NetPPE | 26.56M | 30.34M | 31.10M | 4.48M |
| AccumulatedDepreciation | -6.12M | -3.67M | -1.40M | -559.00K |
| GrossPPE | 32.68M | 34.01M | 32.50M | 5.04M |
| Leases | 2.46M | 2.44M | 1.78M | 408.00K |
| ConstructionInProgress | 41.00K | 27.00K | 482.00K | 646.00K |
| OtherProperties | 8.08M | 7.63M | 5.51M | 1.07M |
| MachineryFurnitureEquipment | 2.00M | 1.91M | 1.42M | 138.00K |
| BuildingsAndImprovements | 20.10M | 22.00M | 23.32M | 2.77M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 296.47M | 270.77M | 264.97M | 222.63M |
| OtherCurrentAssets | 9.39M | 5.06M | 4.43M | 2.95M |
| RestrictedCash | 0.00 | 1.25M | 0.00 | |
| PrepaidAssets | 4.43M | 2.95M | ||
| CashCashEquivalentsAndShortTermInvestments | 287.08M | 265.71M | 259.28M | 219.68M |
| OtherShortTermInvestments | 188.91M | 212.48M | 119.39M | 0.00 |
| CashAndCashEquivalents | 98.17M | 53.23M | 139.89M | 219.68M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -208.36M | -156.42M | -125.50M | -60.48M |
| IssuanceOfCapitalStock | 213.34M | 161.82M | 161.94M | 38.01M |
| CapitalExpenditure | -573.00K | -2.80M | -6.86M | -1.72M |
| EndCashPosition | 98.17M | 53.23M | 141.14M | 220.94M |
| BeginningCashPosition | 53.23M | 141.14M | 220.94M | 243.44M |
| ChangesInCash | 44.94M | -87.91M | -79.80M | -22.51M |
| FinancingCashFlow | 214.45M | 163.54M | 163.56M | 37.98M |
| CashFlowFromContinuingFinancingActivities | 214.45M | 163.54M | 163.56M | 37.98M |
| NetOtherFinancingCharges | -85.00K | |||
| ProceedsFromStockOptionExercised | 1.11M | 1.72M | 1.61M | 55.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 213.34M | 161.82M | 161.94M | 38.01M |
| CommonStockIssuance | 213.34M | 161.82M | 161.94M | 38.01M |
| InvestingCashFlow | 38.28M | -97.82M | -124.72M | -1.72M |
| CashFlowFromContinuingInvestingActivities | 38.28M | -97.82M | -124.72M | -1.72M |
| NetInvestmentPurchaseAndSale | 38.85M | -95.03M | -117.86M | 0.00 |
| SaleOfInvestment | 294.45M | 253.78M | 60.00M | 0.00 |
| PurchaseOfInvestment | -255.60M | -348.80M | -177.85M | 0.00 |
| NetPPEPurchaseAndSale | -573.00K | -2.80M | -6.86M | -1.72M |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -573.00K | -2.80M | -6.86M | -1.72M |
| OperatingCashFlow | -207.79M | -153.62M | -118.64M | -58.76M |
| CashFlowFromContinuingOperatingActivities | -207.79M | -153.62M | -118.64M | -58.76M |
| ChangeInWorkingCapital | 11.60M | 11.44M | 751.00K | 176.00K |
| ChangeInOtherCurrentLiabilities | -1.39M | -796.00K | -8.69M | -2.05M |
| ChangeInOtherCurrentAssets | 2.00K | -119.00K | -1.02M | -3.73M |
| ChangeInPayablesAndAccruedExpense | 17.31M | 12.98M | 11.95M | 6.18M |
| ChangeInAccruedExpense | 15.96M | 8.17M | 9.59M | 3.43M |
| ChangeInPayable | 1.36M | 4.81M | 2.36M | 2.75M |
| ChangeInAccountPayable | 1.36M | 4.81M | 2.36M | 2.75M |
| ChangeInPrepaidAssets | -4.33M | -626.00K | -1.49M | -227.00K |
| ChangeInReceivables | 0.00 | |||
| ChangesInAccountReceivables | 0.00 | |||
| OtherNonCashItems | -1.70M | -1.36M | -343.00K | |
| StockBasedCompensation | 39.74M | 30.62M | 18.37M | 11.69M |
| AssetImpairmentCharge | 0.00 | 0.00 | -396.00K | 0.00 |
| AmortizationOfSecurities | -7.62M | -5.17M | -1.64M | 0.00 |
| DepreciationAmortizationDepletion | 4.35M | 3.59M | 5.88M | 1.99M |
| DepreciationAndAmortization | 4.35M | 3.59M | 5.88M | 1.99M |
| Depreciation | 4.35M | 3.59M | 5.88M | 1.99M |
| OperatingGainsLosses | 8.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 8.00K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -255.86M | -192.41M | -140.24M | -72.27M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for COGT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|